The article is titled "The Role and Therapeutic Targeting of CCR5 in Breast Cancer" and specifically mentions Leronlimab as a humanized monoclonal antibody that acts as a CCR5 inhibitor, showing anti-tumor and anti-metastatic properties in preclinical studies. It discusses how CCR5 antagonists, including Leronlimab, may be promising therapeutics for breast cancer.



https://www.mdpi.com/2073-4409/12/18/2237